

**Supplementary Table 2. Comparison of long-term outcomes between study group and historical group**

	2-year RFS, %	2-year OS, %	4-year RFS, %	4-year OS, %
Rituximab including group				
Overall patients	55.3	60.8	40.2	48.0
Ph-positive	60.7	73.3	52.1	52.3
Ph-negative	50.4	51.5	35.7	43.2
Historical group				
Overall patients	39.7	45.1	30.9	32.9
Ph-positive	60.9	56.7	40.6	45.3
Ph-negative	34.4	42.1	27.3	30.0

RFS, relapse-free survival; OS, overall survival; Ph, Philadelphia.